{"transactions":[{"id":741988,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T00:00:09.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":17096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":17096,"derivative":{"exercise_price":6.69,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":17096},"source":{"system":"sec-edgar","filing":"0001193125-26-268168","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022626/000119312526268168/ownership.xml","form_type":"4"}},{"id":741293,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T20:05:10.000Z","date":"2026-06-09","kind":"exercise","planned":false,"acquired":false,"shares":38094,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vested and became exercisable as to 33% of the total shares on September 9, 2025 and thereafter in 24 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":817826,"derivative":{"exercise_price":5.25,"expiration_date":"2034-09-19","underlying":"Common Stock","underlying_shares":38094},"source":{"system":"sec-edgar","filing":"0001193125-26-267493","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1354434/000119312526267493/ownership.xml","form_type":"4"}},{"id":741292,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-06-11T20:05:10.000Z","date":"2026-06-09","kind":"exercise","planned":false,"acquired":true,"shares":38094,"price":5.25,"value":199993.5,"ownership":{"direct":true},"balance_after":38094,"source":{"system":"sec-edgar","filing":"0001193125-26-267493","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1354434/000119312526267493/ownership.xml","form_type":"4"}},{"id":804349,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:18:00.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest and become exercisable, if at all,  as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the \"Performance Measurement Period\"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date."}],"balance_after":300000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001193125-26-164299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1354434/000119312526164299/ownership.xml","form_type":"4"}},{"id":804348,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:18:00.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":300000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001193125-26-164299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1354434/000119312526164299/ownership.xml","form_type":"4"}},{"id":1113806,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:17:33.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":17096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest upon the earlier of (i) June 10, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":17096,"derivative":{"exercise_price":11.59,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":17096},"source":{"system":"sec-edgar","filing":"0000950170-25-085373","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022626/000095017025085373/ownership.xml","form_type":"4"}},{"id":1386803,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-15T20:15:08.000Z","date":"2024-10-10","kind":"grant","planned":false,"acquired":true,"shares":17096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest upon the earlier of (i) October 10, 2025 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":17096,"derivative":{"exercise_price":17,"expiration_date":"2034-10-09","underlying":"Common Stock","underlying_shares":17096},"source":{"system":"sec-edgar","filing":"0000950170-24-114687","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022626/000095017024114687/ownership.xml","form_type":"4"}},{"id":1440916,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Performance-based Restricted Stock Units","published_at":"2024-08-05T16:36:25.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":320742,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"At the Effective Time, each outstanding award of performance-based restricted stock units (\"PSUs\") was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares subject to such PSUs, determined assuming that the applicable performance goals had been deemed to be achieved at the greater of target and actual level of performance, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"At the Effective Time, each outstanding award of performance-based restricted stock units (\"PSUs\") was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares subject to such PSUs, determined assuming that the applicable performance goals had been deemed to be achieved at the greater of target and actual level of performance, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"At the Effective Time, each outstanding award of performance-based restricted stock units (\"PSUs\") was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares subject to such PSUs, determined assuming that the applicable performance goals had been deemed to be achieved at the greater of target and actual level of performance, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":320742},"source":{"system":"sec-edgar","filing":"0000950170-24-090851","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090851/ownership.xml","form_type":"4"}},{"id":1440915,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Restricted Stock Units","published_at":"2024-08-05T16:36:25.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":284023,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"At the Effective Time, (a) 50% of each outstanding award of restricted stock units (\"RSUs\") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, (a) 50% of each outstanding award of restricted stock units (\"RSUs\") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, (a) 50% of each outstanding award of restricted stock units (\"RSUs\") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":284023},"source":{"system":"sec-edgar","filing":"0000950170-24-090851","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090851/ownership.xml","form_type":"4"}},{"id":1440914,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-05T16:36:25.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":215749,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":215749},"source":{"system":"sec-edgar","filing":"0000950170-24-090851","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090851/ownership.xml","form_type":"4"}},{"id":1440913,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-08-05T16:36:25.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":83857,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 6, 2023, by and among AbbVie Inc. (\"Parent\"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. (\"Merger Sub\") and Cerevel Therapeutics Holdings, Inc. (\"Issuer\"), on August 1, 2024 (the \"Effective Time\"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the \"Merger Consideration\"), without interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by The Ronald C Renaud Jr Trust 2 U/A DTD 06/08/2007, of which the Reporting Person and his spouse serve as trustees. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-090851","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090851/ownership.xml","form_type":"4"}},{"id":1440912,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-08-05T16:36:25.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":160452,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 6, 2023, by and among AbbVie Inc. (\"Parent\"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. (\"Merger Sub\") and Cerevel Therapeutics Holdings, Inc. (\"Issuer\"), on August 1, 2024 (the \"Effective Time\"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the \"Merger Consideration\"), without interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-090851","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090851/ownership.xml","form_type":"4"}},{"id":1673138,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Restricted Stock Units","published_at":"2024-01-23T17:31:54.000Z","date":"2024-01-19","kind":"grant","planned":false,"acquired":true,"shares":284023,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":284023,"derivative":{"underlying":"Common Stock","underlying_shares":284023},"source":{"system":"sec-edgar","filing":"0000950170-24-006667","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024006667/ownership.xml","form_type":"4"}},{"id":1702294,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Restricted Stock Units","published_at":"2023-12-21T20:18:31.000Z","date":"2023-12-19","kind":"exercise","planned":false,"acquired":false,"shares":160452,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represented the contingent right to receive one share of the Issuer's common stock."},{"field":"kind","element":"transactionCoding","label":"F1","text":"In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the \"Issuer\"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units (\"RSUs\") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the \"Issuer\"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units (\"RSUs\") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the \"Issuer\"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units (\"RSUs\") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":160452},"source":{"system":"sec-edgar","filing":"0000950170-23-072374","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023072374/ownership.xml","form_type":"4"}},{"id":1702293,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-12-21T20:18:31.000Z","date":"2023-12-19","kind":"exercise","planned":false,"acquired":true,"shares":160452,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the \"Issuer\"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units (\"RSUs\") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represented the contingent right to receive one share of the Issuer's common stock."}],"balance_after":160452,"source":{"system":"sec-edgar","filing":"0000950170-23-072374","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023072374/ownership.xml","form_type":"4"}},{"id":1813899,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-08-07T17:13:43.000Z","date":"2023-08-03","kind":"purchase","planned":false,"acquired":true,"shares":83857,"price":23.9552,"value":2008811.2064,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.78 - $24.01. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by The Ronald C Renaud Jr Trust 2 U/A DTD 06/08/2007, of which the Reporting Person and his spouse serve as trustees. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":83857,"source":{"system":"sec-edgar","filing":"0000950170-23-039169","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023039169/ownership.xml","form_type":"4"}},{"id":1855991,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Performance-based Restricted Stock Units","published_at":"2023-06-14T16:53:07.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":160371,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The shares reported in this transaction represent the target number of performance-based RSUs (\"PSUs\") granted under the Plan. The PSUs shall vest at the end of a four-year performance period following the Grant Date based on absolute total stockholder return (\"TSR\") performance measured at the end of the performance period (with a payout range of 0% to 250% of the target number of PSUs, or 50% to 275% of the target number of PSUs upon a Sale Event (as defined in an Employment Agreement between the Issuer and the Reporting Person)), subject to the Reporting Person's continued service at such time. Excludes an additional 160,371 target PSUs issued on the same Grant Date that are subject to vesting based on certain relative TSR performance metrics."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares reported in this transaction represent the target number of performance-based RSUs (\"PSUs\") granted under the Plan. The PSUs shall vest at the end of a four-year performance period following the Grant Date based on absolute total stockholder return (\"TSR\") performance measured at the end of the performance period (with a payout range of 0% to 250% of the target number of PSUs, or 50% to 275% of the target number of PSUs upon a Sale Event (as defined in an Employment Agreement between the Issuer and the Reporting Person)), subject to the Reporting Person's continued service at such time. Excludes an additional 160,371 target PSUs issued on the same Grant Date that are subject to vesting based on certain relative TSR performance metrics."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares reported in this transaction represent the target number of performance-based RSUs (\"PSUs\") granted under the Plan. The PSUs shall vest at the end of a four-year performance period following the Grant Date based on absolute total stockholder return (\"TSR\") performance measured at the end of the performance period (with a payout range of 0% to 250% of the target number of PSUs, or 50% to 275% of the target number of PSUs upon a Sale Event (as defined in an Employment Agreement between the Issuer and the Reporting Person)), subject to the Reporting Person's continued service at such time. Excludes an additional 160,371 target PSUs issued on the same Grant Date that are subject to vesting based on certain relative TSR performance metrics."}],"balance_after":160371,"derivative":{"underlying":"Common Stock","underlying_shares":160371},"source":{"system":"sec-edgar","filing":"0000899243-23-015539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323015539/doc4.xml","form_type":"4"}},{"id":1855990,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Restricted Stock Units","published_at":"2023-06-14T16:53:07.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":160452,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of June 12, 2024, June 12, 2025, June 12, 2026 and June 12, 2027, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of June 12, 2024, June 12, 2025, June 12, 2026 and June 12, 2027, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of June 12, 2024, June 12, 2025, June 12, 2026 and June 12, 2027, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":160452,"derivative":{"underlying":"Common Stock","underlying_shares":160452},"source":{"system":"sec-edgar","filing":"0000899243-23-015539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323015539/doc4.xml","form_type":"4"}},{"id":1855989,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-14T16:53:07.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":215749,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on June 12, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":215749,"derivative":{"exercise_price":32.72,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":215749},"source":{"system":"sec-edgar","filing":"0000899243-23-015539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323015539/doc4.xml","form_type":"4"}},{"id":2220946,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2022-06-27T20:48:01.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":31500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":31500,"derivative":{"exercise_price":7.35,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":31500},"source":{"system":"sec-edgar","filing":"0001140361-22-024159","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1354434/000114036122024159/form4.xml","form_type":"4"}},{"id":2220945,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-06-27T20:48:01.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":31500,"source":{"system":"sec-edgar","filing":"0001140361-22-024159","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1354434/000114036122024159/form4.xml","form_type":"4"}},{"id":2233785,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-13T22:09:54.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":13419,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 9, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."}],"balance_after":13419,"derivative":{"exercise_price":4.85,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":13419},"source":{"system":"sec-edgar","filing":"0000899243-22-022239","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1354434/000089924322022239/doc4.xml","form_type":"4"}},{"id":2459390,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-23T23:35:19.000Z","date":"2021-12-21","kind":"grant","acquired":true,"shares":13419,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest (1) 25% on December 21, 2022, and the remaining shall vest in equal monthly installments over the next 36 months."}],"balance_after":13419,"derivative":{"exercise_price":14.92,"expiration_date":"2031-12-21","underlying":"Common Stock","underlying_shares":13419},"source":{"system":"sec-edgar","filing":"0000899243-21-049685","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1354434/000089924321049685/doc4.xml","form_type":"4"}},{"id":2570852,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-14T19:32:44.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":89996,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was granted on March 7, 2018.  The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 7, 2019 and the remainder vesting in equal monthly installment through March 7, 2022."}],"balance_after":0,"derivative":{"exercise_price":8.34,"expiration_date":"2028-03-06","underlying":"Common Stock","underlying_shares":89996},"source":{"system":"sec-edgar","filing":"0001209191-21-056062","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121056062/doc4.xml","form_type":"4"}},{"id":2570851,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-14T19:32:44.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":1071009,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on December 22, 2017.  The shares underlying became fully vested on March 9, 2021."}],"balance_after":0,"derivative":{"exercise_price":7.39,"expiration_date":"2027-12-21","underlying":"Common Stock","underlying_shares":1071009},"source":{"system":"sec-edgar","filing":"0001209191-21-056062","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121056062/doc4.xml","form_type":"4"}},{"id":2570850,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stcok Option (right to buy)","published_at":"2021-09-14T19:32:44.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on March 9, 2021. This option will vest as to 25% of the shares on March 9, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 9, 2025."}],"balance_after":0,"derivative":{"exercise_price":23.82,"expiration_date":"2031-03-09","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001209191-21-056062","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121056062/doc4.xml","form_type":"4"}},{"id":2570849,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-14T19:32:44.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":525000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on March 3, 2020. This option will vest as to 25% of the shares on March 3, 2021, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 3, 2024."}],"balance_after":0,"derivative":{"exercise_price":7.66,"expiration_date":"2030-03-02","underlying":"Common Stock","underlying_shares":525000},"source":{"system":"sec-edgar","filing":"0001209191-21-056062","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121056062/doc4.xml","form_type":"4"}},{"id":2570848,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-14T19:32:44.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 8, 2019. This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023."}],"balance_after":0,"derivative":{"exercise_price":7.95,"expiration_date":"2029-03-07","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-21-056062","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121056062/doc4.xml","form_type":"4"}},{"id":2570847,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-09-14T19:32:44.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":40909,"price":38,"value":1554542.0,"ownership":{"direct":false,"nature":"By Ronald C. Renaud, Jr. Trust - 2007"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the \"Tender Offer\"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021."},{"field":"kind","element":"transactionCoding","label":"F1","text":"As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the \"Tender Offer\"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-056062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121056062/doc4.xml","form_type":"4"}},{"id":2570846,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-09-14T19:32:44.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":409913,"price":38,"value":15576694.0,"ownership":{"direct":false,"nature":"By Ronald Renaud 2014 Irrevocable Family Trust"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the \"Tender Offer\"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021."},{"field":"kind","element":"transactionCoding","label":"F1","text":"As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the \"Tender Offer\"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-056062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121056062/doc4.xml","form_type":"4"}},{"id":2570845,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-09-14T19:32:44.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":503231,"price":38,"value":19122778.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the \"Tender Offer\"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021."},{"field":"kind","element":"transactionCoding","label":"F1","text":"As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the \"Tender Offer\"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-056062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121056062/doc4.xml","form_type":"4"}},{"id":2570843,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-14T19:31:11.000Z","date":"2021-04-07","kind":"exercise","acquired":false,"shares":9026,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on December 22, 2017.  The shares underlying the option vested over four years in equal monthly installments through March 9, 2021."}],"balance_after":1071009,"derivative":{"exercise_price":7.39,"expiration_date":"2027-12-21","underlying":"Common Stock","underlying_shares":9026},"source":{"system":"sec-edgar","filing":"0001209191-21-056060","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121056060/doc4a.xml","form_type":"4/A","original_submission_date":"2021-04-09"}},{"id":2570842,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-09-14T19:31:11.000Z","date":"2021-04-07","kind":"exercise","acquired":true,"shares":9026,"price":7.39,"value":66702.14,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The original Form 4 filed on April 9, 2021 inadvertently reported the incorrect number of securities beneficially owned following the reported transaction by an additional 90 shares. The original Form 4 filed on April 9, 2021 stated that 503,321 shares were owned after the transaction.  The correct number of shares is 503,231.  This amendment is being filed solely to correct the number of securities beneficially owned."}],"balance_after":503231,"source":{"system":"sec-edgar","filing":"0001209191-21-056060","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121056060/doc4a.xml","form_type":"4/A","original_submission_date":"2021-04-09"}},{"id":2675266,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2021-06-09T23:13:08.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":17500,"derivative":{"exercise_price":13.8,"expiration_date":"2031-06-07","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001140361-21-020441","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1354434/000114036121020441/form4.xml","form_type":"4"}},{"id":2675265,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-06-09T23:13:08.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":11000,"source":{"system":"sec-edgar","filing":"0001140361-21-020441","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1354434/000114036121020441/form4.xml","form_type":"4"}},{"id":2752155,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-04-09T16:14:09.000Z","date":"2021-04-07","kind":"exercise","acquired":false,"shares":9026,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on December 22, 2017.  The shares underlying the option vested over four years in equal monthly installments through March 9, 2021."}],"balance_after":1071009,"derivative":{"exercise_price":7.39,"expiration_date":"2027-12-21","underlying":"Common Stock","underlying_shares":9026},"source":{"system":"sec-edgar","filing":"0001209191-21-026217","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121026217/doc4.xml","form_type":"4"}},{"id":2752154,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-04-09T16:14:09.000Z","date":"2021-04-07","kind":"exercise","acquired":true,"shares":9026,"price":7.39,"value":66702.14,"ownership":{"direct":true},"balance_after":503321,"source":{"system":"sec-edgar","filing":"0001209191-21-026217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121026217/doc4.xml","form_type":"4"}},{"id":2800075,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer, Pres."}}],"security":"Stock Option (right to buy)","published_at":"2021-03-09T20:27:48.000Z","date":"2021-03-09","kind":"grant","acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest as to 25% of the shares on March 9, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares though March 9, 2025."}],"balance_after":325000,"derivative":{"exercise_price":23.82,"expiration_date":"2031-03-09","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001209191-21-019305","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121019305/doc4.xml","form_type":"4"}},{"id":2907267,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer, Pres."}}],"security":"Stock Option (right to buy)","published_at":"2021-01-14T19:59:06.000Z","date":"2021-01-14","kind":"exercise","acquired":false,"shares":1,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 7, 2018.  The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 7, 2019 and the remainder vesting in equal monthly installment through March 7, 2022."}],"balance_after":89996,"derivative":{"exercise_price":8.34,"expiration_date":"2028-03-06","underlying":"Common Stock","underlying_shares":1},"source":{"system":"sec-edgar","filing":"0001209191-21-003697","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121003697/doc4.xml","form_type":"4"}},{"id":2907266,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer, Pres."}}],"security":"Stock Option (right to buy)","published_at":"2021-01-14T19:59:06.000Z","date":"2021-01-14","kind":"exercise","acquired":false,"shares":5638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on December 22, 2017.  The shares underlying the option are scheduled to vest over four years in equal monthly installments through March 9, 2021."}],"balance_after":1080035,"derivative":{"exercise_price":7.39,"expiration_date":"2027-12-21","underlying":"Common Stock","underlying_shares":5638},"source":{"system":"sec-edgar","filing":"0001209191-21-003697","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121003697/doc4.xml","form_type":"4"}},{"id":2907265,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer, Pres."}}],"security":"Common Stock","published_at":"2021-01-14T19:59:06.000Z","date":"2021-01-14","kind":"exercise","acquired":true,"shares":1,"price":8.34,"value":8.34,"ownership":{"direct":true},"balance_after":494205,"source":{"system":"sec-edgar","filing":"0001209191-21-003697","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121003697/doc4.xml","form_type":"4"}},{"id":2907264,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer, Pres."}}],"security":"Common Stock","published_at":"2021-01-14T19:59:06.000Z","date":"2021-01-14","kind":"exercise","acquired":true,"shares":5638,"price":7.39,"value":41664.82,"ownership":{"direct":true},"balance_after":494204,"source":{"system":"sec-edgar","filing":"0001209191-21-003697","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121003697/doc4.xml","form_type":"4"}},{"id":2975337,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer, Pres."}}],"security":"Stock Option (right to buy)","published_at":"2020-11-18T19:30:43.000Z","date":"2020-11-16","kind":"exercise","acquired":false,"shares":3,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 7, 2018. 25% of the shares vested on March 7, 2019 and the remainder are scheduled to vest in equal monthly installment through March 7, 2022."}],"balance_after":89997,"derivative":{"exercise_price":8.34,"expiration_date":"2028-03-06","underlying":"Common Stock","underlying_shares":3},"source":{"system":"sec-edgar","filing":"0001209191-20-059255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919120059255/doc4.xml","form_type":"4"}},{"id":2975336,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer, Pres."}}],"security":"Stock Option (right to buy)","published_at":"2020-11-18T19:30:43.000Z","date":"2020-11-16","kind":"exercise","acquired":false,"shares":53004,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on December 22, 2017.  The shares underlying the option are scheduled to vest over four years in equal monthly installments through March 9, 2021."}],"balance_after":1085673,"derivative":{"exercise_price":7.39,"expiration_date":"2027-12-21","underlying":"Common Stock","underlying_shares":53004},"source":{"system":"sec-edgar","filing":"0001209191-20-059255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919120059255/doc4.xml","form_type":"4"}},{"id":2975335,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer, Pres."}}],"security":"Common Stock","published_at":"2020-11-18T19:30:43.000Z","date":"2020-11-16","kind":"exercise","acquired":true,"shares":3,"price":8.34,"value":25.02,"ownership":{"direct":true},"balance_after":488566,"source":{"system":"sec-edgar","filing":"0001209191-20-059255","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919120059255/doc4.xml","form_type":"4"}},{"id":2975334,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer, Pres."}}],"security":"Common Stock","published_at":"2020-11-18T19:30:43.000Z","date":"2020-11-16","kind":"exercise","acquired":true,"shares":53004,"price":7.39,"value":391699.56,"ownership":{"direct":true},"balance_after":488563,"source":{"system":"sec-edgar","filing":"0001209191-20-059255","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919120059255/doc4.xml","form_type":"4"}},{"id":3166319,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2020-04-30T23:44:50.000Z","date":"2020-04-29","kind":"grant","acquired":true,"shares":71500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the shares will vest on the first, second and third anniversaries of the grant date, subject to the Director's Continuous Service (as defined in the Plan)."}],"balance_after":71500,"derivative":{"exercise_price":8.53,"expiration_date":"2030-04-28","underlying":"Common Stock","underlying_shares":71500},"source":{"system":"sec-edgar","filing":"0001209191-20-026420","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1354434/000120919120026420/doc4.xml","form_type":"4"}},{"id":3224648,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Executive Officer","other_text":"President"}}],"security":"Stock Option (right to buy)","published_at":"2020-03-05T19:53:15.000Z","date":"2020-03-03","kind":"grant","acquired":true,"shares":525000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest as to 25% of the shares on March 3, 2021, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 3, 2024."}],"balance_after":525000,"derivative":{"exercise_price":7.66,"expiration_date":"2030-03-02","underlying":"Common Stock","underlying_shares":525000},"source":{"system":"sec-edgar","filing":"0001209191-20-016801","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919120016801/doc4.xml","form_type":"4"}},{"id":3480376,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-24T14:30:13.000Z","date":"2019-06-20","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2020 annual stockholder meeting."}],"balance_after":21000,"derivative":{"exercise_price":3.37,"expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001209191-19-038719","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919119038719/doc4.xml","form_type":"4"}},{"id":3599424,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Executive Officer","other_text":"President"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-12T18:14:13.000Z","date":"2019-03-08","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023."}],"balance_after":500000,"derivative":{"exercise_price":7.95,"expiration_date":"2029-03-07","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-19-018962","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919119018962/doc4.xml","form_type":"4"}},{"id":3875554,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Series C Preferred Stock","published_at":"2018-07-03T20:17:40.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":227272,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Ronald C. Renaud, Jr. Trust - 2007"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":40909},"source":{"system":"sec-edgar","filing":"0000899243-18-019367","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000089924318019367/doc4.xml","form_type":"4"}},{"id":3875553,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Series C Preferred Stock","published_at":"2018-07-03T20:17:40.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":227272,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Ronald Renaud 2014 Irrevocable Family Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":40909},"source":{"system":"sec-edgar","filing":"0000899243-18-019367","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000089924318019367/doc4.xml","form_type":"4"}},{"id":3875552,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2018-07-03T20:17:40.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":40909,"ownership":{"direct":false,"nature":"By Ronald C. Renaud, Jr. Trust - 2007"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."}],"balance_after":40909,"source":{"system":"sec-edgar","filing":"0000899243-18-019367","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000089924318019367/doc4.xml","form_type":"4"}},{"id":3875551,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2018-07-03T20:17:40.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":40909,"ownership":{"direct":false,"nature":"By Ronald Renaud 2014 Irrevocable Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."}],"balance_after":409913,"source":{"system":"sec-edgar","filing":"0000899243-18-019367","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000089924318019367/doc4.xml","form_type":"4"}},{"id":3886252,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-21T17:38:17.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2019 annual stockholder meeting."}],"balance_after":21000,"derivative":{"exercise_price":4.82,"expiration_date":"2028-06-19","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001209191-18-039001","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919118039001/doc4.xml","form_type":"4"}},{"id":3892174,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2018-06-15T12:17:05.000Z","date":"2018-06-14","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the \"Company's\") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the \"Stock Option\").  100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company."}],"balance_after":12500,"derivative":{"exercise_price":11.14,"exercise_date":"2019-06-14","expiration_date":"2028-06-14","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001562180-18-003018","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1354434/000156218018003018/primarydocument.xml","form_type":"4"}},{"id":4270313,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-29T16:15:52.000Z","date":"2017-06-28","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2018 annual stockholder meeting."}],"balance_after":21000,"derivative":{"exercise_price":5.53,"expiration_date":"2027-06-27","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001209191-17-042275","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919117042275/doc4.xml","form_type":"4"}},{"id":4277118,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2017-06-19T20:05:40.000Z","date":"2017-06-15","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the option shares vest on the first anniversary of the date of grant (the \"Vesting Date\"), provided that the Reporting Person remains in continuous service as a member of the Issuer's Board of Directors through the Vesting Date, and provided further that the options held by the Reporting Person shall be eligible for vesting acceleration upon a \"Change in Control\" as defined and provided for in the Issuer's Non-Employee Director Stock Option Award Agreement."}],"balance_after":12500,"derivative":{"exercise_price":14.37,"exercise_date":"2018-06-15","expiration_date":"2027-06-15","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001562180-17-002296","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1354434/000156218017002296/primarydocument.xml","form_type":"4"}},{"id":4499409,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right To Buy)","published_at":"2017-01-06T00:24:45.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 3, 2017 and vests over one year in twelve equal monthly installments, commencing on February 3, 2017."}],"balance_after":12000,"derivative":{"exercise_price":11.23,"expiration_date":"2027-01-02","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001070081-17-000039","document":"wf-form4_148366227250178.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008117000039/wf-form4_148366227250178.xml","form_type":"4"}}]}